- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Orchestra BioMed GAAP EPS of -$0.41, revenue of $0.99M | 1 | Seeking Alpha | ||
| 12.11. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update | 94 | GlobeNewswire (Europe) | NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies... ► Artikel lesen | |
| 12.11. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.09. | Orchestra BioMed executive acquires shares worth over $47k | 1 | Investing.com | ||
| 11.09. | Orchestra BioMed director sells over $30k in company shares | 4 | Investing.com | ||
| 11.09. | Orchestra BioMed executive sells over $73k in company stock | 2 | Investing.com | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 07.09. | Orchestra BioMed executive sells over $120k in company stock | 3 | Investing.com | ||
| 13.08. | Orchestra BioMed reports Q2 results | 1 | Seeking Alpha | ||
| 12.08. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update | 111 | GlobeNewswire (Europe) | NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies... ► Artikel lesen | |
| 12.08. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.06. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 11.06. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update | 929 | GlobeNewswire (Europe) | Company hosting in-person R&D day event, focused on atrioventricular interval modulation ("AVIM") therapy, including the unmet need in hypertension, mechanism of action, clinical results and design... ► Artikel lesen | |
| 27.03. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update | 145 | GlobeNewswire (Europe) | Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with... ► Artikel lesen | |
| 06.02. | PurMinds NeuroPharma Selected to Present at the 2024 OBIO Investment Summit | 522 | Newsfile | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 6, 2024) - PurMinds NeuroPharma Inc. ("PurMinds" or the "Company"), a clinical-stage neuroscience company dedicated to the development... ► Artikel lesen | |
| 08.01. | Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients | 247 | GlobeNewswire (Europe) | Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,430 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,379 | +1,61 % | Defence Therapeutics will proprietäre Accum-Technologie an Entwickler von Antikörper-Wirkstoff-Konjugaten (ADC) lizenzieren | Vancouver, BC, Kanada, 29. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das "Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches
Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,750 | -4,89 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | -2,31 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,720 | -5,58 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,860 | -3,91 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,140 | -2,53 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,990 | -3,41 % | Assertio Holdings, Inc.: Assertio Reports Third Quarter 2024 Financial Results | Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,690 | -6,43 % | Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now? | ||
| ADMA BIOLOGICS | 19,820 | +0,66 % | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | ||
| VIR BIOTECHNOLOGY | 9,325 | +14,49 % | Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients | ||
| VERVE THERAPEUTICS | 7,320 | +2,59 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 18,300 | -2,14 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| ARVINAS | 25,160 | -2,18 % | Arvinas Inc.: Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,950 | -2,87 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,35 % bei einem Aktienkurs von 5,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.
